Zimmer Biomet (ZBH) | Financial Analysis & Statements
Zimmer Biomet Holdings, Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.2B
Gross Profit
1.5B
64.68%
Operating Income
282.6M
12.60%
Net Income
137.9M
6.15%
Balance Sheet Metrics
Total Assets
23.1B
Total Liabilities
10.4B
Shareholders Equity
12.7B
Debt to Equity
0.82
Cash Flow Metrics
Operating Cash Flow
491.7M
Free Cash Flow
432.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Zimmer Biomet Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8.2B | 7.7B | 7.4B | 6.9B | 6.8B |
| Cost of Goods Sold | 2.5B | 2.2B | 2.1B | 2.0B | 2.0B |
| Gross Profit | 5.7B | 5.5B | 5.3B | 4.9B | 4.9B |
| Gross Margin % | 69.7% | 71.5% | 71.8% | 70.9% | 71.3% |
| Operating Expenses | |||||
| Research & Development | 458.5M | 437.4M | 458.7M | 406.0M | 435.8M |
| Selling, General & Administrative | 3.3B | 2.9B | 2.8B | 2.8B | 2.8B |
| Other Operating Expenses | - | - | - | 33.8M | 52.8M |
| Total Operating Expenses | 3.7B | 3.4B | 3.3B | 3.2B | 3.3B |
| Operating Income | 1.4B | 1.5B | 1.5B | 1.2B | 1.0B |
| Operating Margin % | 16.5% | 19.9% | 19.6% | 17.2% | 14.7% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 292.8M | 218.0M | 201.2M | 164.8M | 208.4M |
| Other Non-Operating Income | -232.6M | -273.7M | -182.9M | -623.8M | -298.0M |
| Pre-tax Income | 830.8M | 1.0B | 1.1B | 403.5M | 499.0M |
| Income Tax | 125.7M | 131.4M | 42.2M | 112.3M | 53.5M |
| Effective Tax Rate % | 15.1% | 12.7% | 4.0% | 27.8% | 10.7% |
| Net Income | 705.1M | 905.2M | 1.0B | 232.4M | 402.1M |
| Net Margin % | 8.6% | 11.8% | 13.9% | 3.3% | 5.9% |
| Key Metrics | |||||
| EBITDA | 2.5B | 2.5B | 2.4B | 2.0B | 2.0B |
| EPS (Basic) | $3.56 | $4.45 | $4.91 | $1.10 | $1.93 |
| EPS (Diluted) | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 |
| Basic Shares Outstanding | 198000000 | 203100000 | 208700000 | 209600000 | 208600000 |
| Diluted Shares Outstanding | 198000000 | 203100000 | 208700000 | 209600000 | 208600000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Zimmer Biomet Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 591.9M | 525.5M | 415.8M | 375.7M | 378.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.7B | 1.5B | 1.4B | 1.4B | 1.3B |
| Inventory | 2.3B | 2.2B | 2.4B | 2.1B | 2.1B |
| Other Current Assets | 537.2M | 430.0M | 366.1M | 522.9M | 271.0M |
| Total Current Assets | 5.1B | 4.7B | 4.6B | 4.4B | 4.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.9B | 3.6B | 3.7B | 3.7B | 3.5B |
| Goodwill | 24.6B | 22.5B | 22.5B | 22.2B | 23.4B |
| Intangible Assets | 4.7B | 4.6B | 4.9B | 5.1B | 5.5B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.1B | 1.1B | 1.2B | 1.1B | 2.3B |
| Total Non-Current Assets | 18.0B | 16.7B | 16.9B | 16.6B | 18.6B |
| Total Assets | 23.1B | 21.4B | 21.5B | 21.1B | 23.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 303.0M | 194.6M | 410.6M | 354.1M | 306.5M |
| Short-term Debt | 587.1M | 863.0M | 900.0M | 544.3M | 1.6B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 382.0M | 286.0M | 440.8M | 502.8M | 640.5M |
| Total Current Liabilities | 2.6B | 2.5B | 2.9B | 2.4B | 3.5B |
| Non-Current Liabilities | |||||
| Long-term Debt | 6.9B | 5.3B | 5.0B | 5.3B | 5.5B |
| Deferred Tax Liabilities | 244.1M | 352.5M | 357.6M | 474.8M | 558.5M |
| Other Non-Current Liabilities | 626.1M | 744.1M | 652.2M | 632.6M | 548.5M |
| Total Non-Current Liabilities | 7.8B | 6.4B | 6.2B | 6.7B | 7.3B |
| Total Liabilities | 10.4B | 8.9B | 9.0B | 9.0B | 10.8B |
| Equity | |||||
| Common Stock | 3.2M | 3.2M | 3.2M | 3.1M | 3.1M |
| Retained Earnings | 11.6B | 11.1B | 10.4B | 9.6B | 10.3B |
| Treasury Stock | 8.9B | 8.4B | 7.6B | 6.9B | 6.7B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 12.7B | 12.5B | 12.5B | 12.0B | 12.7B |
| Key Metrics | |||||
| Total Debt | 7.5B | 6.2B | 5.9B | 5.9B | 7.1B |
| Working Capital | 2.5B | 2.2B | 1.8B | 2.1B | 1.4B |
Balance Sheet Composition
Zimmer Biomet Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 705.1M | 905.2M | 1.0B | 291.2M | 445.5M |
| Depreciation & Amortization | 1.1B | 996.3M | 951.7M | 926.4M | 937.7M |
| Stock-Based Compensation | 90.2M | 101.0M | 99.8M | 105.0M | 76.0M |
| Working Capital Changes | -206.7M | -133.4M | -340.9M | -414.4M | -220.7M |
| Operating Cash Flow | 1.6B | 1.8B | 1.6B | 843.8M | 1.1B |
| Investing Activities | |||||
| Capital Expenditures | -224.5M | -203.8M | -291.1M | -187.9M | -143.6M |
| Acquisitions | -1.4B | -276.3M | -134.9M | -99.8M | 0 |
| Investment Purchases | -300.9M | -240.3M | -311.7M | -258.3M | -273.6M |
| Investment Sales | - | 22.1M | 33.4M | 89.4M | 1.9M |
| Investing Cash Flow | -1.9B | -735.1M | -692.5M | -522.0M | -434.9M |
| Financing Activities | |||||
| Share Repurchases | -487.0M | -868.0M | -692.2M | -126.4M | 0 |
| Dividends Paid | -190.3M | -196.0M | -200.9M | -201.2M | -200.1M |
| Debt Issuance | 2.5B | 1.4B | 499.8M | 83.0M | 1.6B |
| Debt Repayment | -1.5B | -850.0M | -120.2M | -1.5B | -2.7B |
| Financing Cash Flow | 286.3M | -566.6M | -864.6M | -853.8M | -1.4B |
| Free Cash Flow | 1.4B | 1.1B | 1.2B | 1.1B | 1.3B |
| Net Change in Cash | -41.7M | 519.7M | 82.3M | -532.0M | -727.0M |
Cash Flow Trend
Zimmer Biomet Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.40
Forward P/E
10.42
Price to Book
1.44
Price to Sales
2.23
PEG Ratio
10.42
Profitability Ratios
Profit Margin
8.57%
Operating Margin
13.97%
Return on Equity
5.60%
Return on Assets
3.94%
Financial Health
Current Ratio
1.98
Debt to Equity
61.97
Beta
0.61
Per Share Data
EPS (TTM)
$3.55
Book Value per Share
$64.95
Revenue per Share
$41.57
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ZBH | 18.1B | 26.40 | 1.44 | 5.60% | 8.57% | 61.97 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Medtronic plc | 107.6B | 23.47 | 2.20 | 9.39% | 13.00% | 57.06 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Edwards Lifesciences | 48.5B | 46.49 | 4.73 | 10.38% | 17.39% | 6.82 |
Financial data is updated regularly. All figures are in the company's reporting currency.






